M13-958: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Major Surgery

Grants and Contracts Details

StatusFinished
Effective start/end date6/6/136/30/14

Funding

  • AbbVie Incorporated: $11,806.00